868 / 1498
Study aim
•
To spare the mediastinal radiotherapy (RT) in patients with
“negative PET” after a combined chemo-immunotherapy
Primary endpoint
•
Progression free survival (PFS) at 2-years from randomization
Secondary endpoints
•
Overall survival (OS) at 5-years from registration
•
To define long term toxicities in this patient population
I
NTERNATIONAL
E
XTRANODAL
L
YMPHOMA
S
TUDY
G
ROUP